Compare Regeneron Pharmaceuticals Inc (REGN) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Warner Music Group Corp trades at $27.43 (market cap $14.57B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.9× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| REGN | WMG | |
|---|---|---|
Market Cap | $70.79B | $14.57B |
Sector | Health | Media |
52-Week High | $812.27 | $34.72 |
52-Week Low | $545.46 | $23.65 |
Enterprise Value | $64.74B | $18.77B |
Dividend Yield | 0.56% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Warner Music Group (WMG) trades at $27.945, down 1.36% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but recent quarterly misses. Revenue growth is steady, reaching $6.71B in 2025, though net income margin has compressed to 5.44%. Recent strategic moves include a licensing renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, positioning the company for growth in digital and AI-driven music markets.
WMG presents a compelling long-term opportunity with analyst consensus pointing to significant upside (target $41.00), supported by 66.66% buy ratings. However, risks include competitive pressures in streaming, margin volatility, and execution challenges in integrating AI technologies. The stock's current valuation multiples (P/E 33.4) suggest premium pricing relative to earnings, requiring sustained growth to justify investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
